Lisata Therapeutics, Inc.
LSTA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1,000 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $11,334 | $12,734 | $43,460 | $17,576 |
| G&A Expenses | $12,075 | $12,974 | $14,141 | $11,474 |
| SG&A Expenses | $12,075 | $12,974 | $14,141 | $11,474 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $23,409 | $25,708 | $57,601 | $29,050 |
| Operating Income | -$22,409 | -$25,708 | -$57,601 | -$29,050 |
| % Margin | -2,240.9% | – | – | – |
| Other Income/Exp. Net | $1,626 | $2,538 | $897 | $76 |
| Pre-Tax Income | -$20,783 | -$23,170 | -$56,704 | -$28,974 |
| Tax Expense | -$798 | -$2,330 | -$2,479 | -$1,508 |
| Net Income | -$19,985 | -$20,840 | -$54,225 | -$27,466 |
| % Margin | -1,998.5% | – | – | – |
| EPS | -2.4 | -2.58 | -10.47 | -7.45 |
| % Growth | 7% | 75.4% | -40.5% | – |
| EPS Diluted | -2.4 | -2.58 | -10.47 | -7.45 |
| Weighted Avg Shares Out | 8,329 | 8,073 | 5,180 | 3,688 |
| Weighted Avg Shares Out Dil | 8,329 | 8,073 | 5,180 | 3,688 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,883 | $2,724 | $1,052 | $151 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $174 | $189 | $69 | $55 |
| EBITDA | -$22,235 | -$25,519 | -$57,532 | -$28,995 |
| % Margin | -2,223.5% | – | – | – |